rivenprost

Rivenprost is a small molecule drug that acts as a potent and selective agonist of the prostaglandin E2 receptor subtype EP4. It was originally developed by Ono Pharmaceutical for potential therapeutic use in conditions such as ulcerative colitis and osteoporosis. Rivenprost selectively activates the EP4 receptor over other PGE2 receptor subtypes (EP1, EP2, EP3), leading to increased bone formation by stimulating osteoblast differentiation and function. It has also been investigated for its ability to prevent bone loss in osteoporosis, stabilize bone implants, support wound healing, and potentially treat inflammatory diseases through barrier-protective effects on endothelial cells. Clinical development reached phase II for ulcerative colitis before being discontinued[1][2][3][4][5][6][7].

Other names

rivenprost [INN]256382-08-8UNII-1WBO45T413UNII1WBO45T413UNII 1WBO45T413methyl 4-[2-[ (1R,2R,3R)-3-hydroxy -2-[ (E,3S)-3-hydroxy -4-[3-(methoxymethyl)phenyl]but -1-enyl ] -5 -oxocyclopentyl ] ethylsulfanyl ] butanoateONO-AE1–734